drugset / Trial / NCT03076164
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety, tolerability and overall response rate of trametinib when given in combination with erlotinib in patients with Stage IV or recurrent lung adenocarcinoma that cannot be treated with curative intent.
Timeline
- Start
- 2017-03-01
- Primary completion
- 2020-12-18
- Completion
- 2020-12-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 75 mg | Oral |
| Subject | Erlotinib | Small molecule | 100 mg | Oral |
| Subject | Trametinib | Small molecule | 1 mg | Oral |
| Subject | Trametinib | Small molecule | 1.5 mg | Oral |